Last updated: October 27, 2026
No. CPC (cell processing center) registration does not prove that a treatment is effective for your condition. It concerns the facility processing the cells, not a clinical finding that those cells improve health. Japan’s Ministry of Health, Labour and Welfare (MHLW) counted 3,671 domestic processing facilities as of June 30, 2026; that is a facility count, not a treatment success rate. Manufacturiungfacility 001590173.pdf

Before paying, separate three questions: where the cells are processed, what treatment plan or product is being offered, and what human evidence supports that exact treatment. Japan regulates cell-therapy practice under the Act on the Safety of Regenerative Medicine (ASRM) and the commercialization of regenerative medical products under the Pharmaceuticals, Medical Devices, and Other Therapeutic Products Act (PMD Act). These are different regulatory routes, not interchangeable endorsements. 0003
What CPC registration actually covers
A cell processing center in Japan is a facility that processes cells. For the ASRM facility route discussed here, the relevant procedures are notification, permission, or certification. The facility has legal duties covering equipment, manufacturing and quality controls, staff, and records. Cells manufactured as marketed regenerative medical products fall under a separate framework. Manufacturiungfacility
| Where cells are processed | Route | Recipient | PMDA facility survey before clearance |
|---|---|---|---|
| Inside a domestic medical institution | Notification | Regional bureau of health and welfare | No PMDA survey; must still meet legal standards |
| Outside a medical institution, in Japan | Permission | MHLW | PMDA survey |
| Outside Japan | Certification | MHLW | PMDA survey |
Notification does not involve the pre-clearance PMDA survey required for permission and certification. All three routes carry legal obligations, but none is a clinical efficacy assessment. A listing also does not prove that every batch meets its release specifications or that a particular patient can safely receive the treatment. Manufacturiungfacility
ASRM amendments took effect on May 31, 2025. Use current official records rather than relying only on a brochure or an old screenshot. Index
What the facility counts mean
The June 30, 2026 snapshot recorded 3,586 notifications and 85 permissions, totaling 3,671 domestic facilities, plus 19 overseas certifications. It separately counted 6,743 treatment-related plans. About 98% of the domestic facilities used notification. These figures count facilities and plans, not patients, recoveries, or adverse events. 001590173.pdf
Four records that answer different questions
| Question | What to check | What it does not prove |
|---|---|---|
| Is the facility allowed to process cells? | Facility notification, permission, or certification | That the treatment works |
| Is the treatment plan filed? | The public treatment-plan registry | That the plan was tested in a controlled trial |
| Is the product approved? | Official product approval information and PMDA review documents for the exact indication | That the result applies to another product, dose, or disease |
| Is there evidence for my case? | Human studies matching diagnosis, stage, product, dose, route, and endpoint | That you personally will benefit |
A clinic service provided under the ASRM is not the same thing as a marketed product approved under the PMD Act. A facility notice and a filed plan cannot, by themselves, establish either product approval or compliance with every requirement of the law. An experimental intervention should be described as experimental; approval of another product does not transfer to it. 0003
What the public registry tells you
MHLW lists the provider name, address, and manager alongside the treatment name and risk class. Each entry also names the review committee, posts the explanation and consent templates, and notes any orders issued under the law. 0000186471 Compare that entry line by line with the brochure before you pay.
The published registry fields do not provide a standardized outcome table for pain, function, survival, or complications. A plan record is therefore not a substitute for clinical results, even if attached documents discuss expected benefits or risks. 0000186471 Keep the distinction between registration and treatment approval in mind when reading a clinic’s wording.
What a product review can show
Stemirac illustrates why even a product decision needs context. In December 2018, it received conditional, time-limited approval for neurological symptoms and functional disorders associated with traumatic spinal cord injury, limited to American Spinal Injury Association Impairment Scale (AIS) grades A to C. The original approval had a seven-year time limit and required post-marketing evaluation. This is a historical example of the evidence reviewed in 2018, not confirmation of current authorization or availability. 0004 000231946.pdf
The single-site, open-label, uncontrolled phase II study treated 13 people with cervical spinal cord injury using one intravenous infusion of their own bone marrow-derived mesenchymal stem cells. The protocol dose range was 50 million to 200 million cells. Twelve of the 13 had an improvement of at least one AIS grade at 220 days (±14 days) after injury, compared with their assessment immediately before treatment. That is not 220 days after infusion, nor is it a controlled treatment effect. 000231946.pdf
PMDA said spontaneous recovery, rehabilitation, and other factors could not be excluded and that control data should have been obtained. All 13 treated patients had post-treatment adverse events: 162 events in total, with no deaths or serious adverse events in this small study. Events occurring after treatment are not necessarily caused by it; these findings also cannot establish safety for a wider population. 000231946.pdf
What knee trials actually found
A 2025 international Cochrane review of stem cell injections for knee osteoarthritis included 25 randomized trials with 1,341 participants across several comparators. Not all contributed to the placebo comparisons below. The primary assessment period for pain and function was three to six months. 40169165
| Outcome versus placebo | Evidence contributing to this estimate | Result |
|---|---|---|
| Pain, 0–10 scale; lower is better | 7 trials, 445 participants | Placebo mean 4.5; stem cell injections averaged 1.2 points better (95% confidence interval: 0 to 2.5 points better). Low certainty. |
| Function, 0–100 scale; lower is better | 7 trials, 432 participants | Placebo mean 46.3; stem cell injections averaged 14.2 points better (95% confidence interval: 3.1 to 25.3 points better). Low certainty. |
These estimates suggest a possible slight improvement, not a predictable result for an individual. The pain interval includes no difference. Cell sources, preparation methods, and doses varied, and none of the included trials assessed radiographic progression. Symptom scores therefore do not establish that cartilage regenerated. 40169165
Serious adverse events occurred in 4 of 242 participants receiving stem cells and 5 of 219 receiving placebo (risk ratio 0.72; 95% confidence interval 0.20 to 2.64). The review rated this evidence very low certainty; the small event counts do not establish equal safety or absence of risk. These results concern knee osteoarthritis injections, not intravenous treatments or other diseases. 40169165
A document check you can repeat
Suppose a clinic shows you a facility number and says its treatment is government-approved. First check which facility and processing address the number identifies. Then ask for the exact treatment-plan entry: MHLW’s provider information identifies the treatment, provider, review committee, and consent documents. Matching these records answers identity and filing questions, not whether the treatment works. This is a hypothetical checking scenario, not a patient case. 0000186471
Next open the clinical evidence. The Stemirac review, for example, gives a patient denominator of 13, a defined AIS endpoint, and no control group. The knee review separates its overall 1,341 participants from the 445 contributing to its placebo pain estimate. Those are details a facility number cannot supply. This document-based approach does not involve examining patients or judging anyone’s treatment eligibility. 000231946.pdf 40169165
What evidence must match your case
Ask the treating physician whether the human studies match your diagnosis and treatment on five points:
- Disease and stage. Check the diagnostic criteria, severity, and eligibility criteria, not just the disease name.
- Cell product. Source, donor type, culture steps, formulation, and potency change the product.
- Dose and route. Evidence for a joint injection cannot simply be transferred to an intravenous infusion, spinal-fluid injection, or implant.
- Comparator. Placebo, sham, standard care, or another treatment.
- Endpoint and follow-up. Pain, function, imaging, survival, or quality of life, measured at a set time.
Ask for the number treated, the number evaluated at each follow-up, and the definition of improvement behind any success rate. An uncontrolled series cannot separate treatment effects from natural recovery or other care, as the Stemirac review demonstrates. Even pooled randomized evidence can remain uncertain, as the knee review shows. 000231946.pdf 40169165
Harm data belong in the same request. Ask how many had serious events, how many quit over side effects, and how the team handled problems. Risk changes with the source, processing, route, dose, and your health. A facility paper cannot answer that.
How to check before paying
- Write down the exact facility name, number, and processing address. If your cells travel elsewhere, that other site’s status counts.
- Confirm the route: notification, permission, or certification.
- Copy the exact plan name and registry entry, with provider, treatment, class, committee, and consent form.
- When staff say approved, ask for the product name, indication, dose, approval date, and current prescribing information. PMDA’s April 2015–May 2026 list is a starting point for checking recorded approvals, not a complete current-status record. For conditional approvals, ask for confirmation of the current authorization and its conditions rather than relying on the original approval date. 000281990.pdf
- Ask for the human study report, not just a trial registration number. Registration records a study; it does not establish a favorable result or authorize marketing. As a separate U.S. comparison, FDA warns that ClinicalTrials.gov inclusion or FDA registration does not mean a product is legally marketed. This is U.S. guidance, not Japanese law. Important patient and consumer information about regenerative medicine therapies
- Read the study’s methods and results even if it appears in PubMed. Indexing is not an efficacy verdict. NLM’s MEDLINE selection evaluates journals’ scientific and editorial quality; it does not certify an individual treatment claim or replace assessment of a study’s design. Medline_journal_selection
- Collect the consent form and an itemized quote before you pay anything you cannot get back. The form should spell out risks, choices, and follow-up.
- Show it all to the doctor who manages your condition before you change standard care.
Use that same habit of checking papers first when choosing a hospital.
Registration claims that should worry you
Pause and ask for independent medical advice if the clinic uses any of these claims or pressures:
- Guaranteed results, a cure, or zero side effects.
- Registration used as the main proof of benefit.
- MHLW-approved with no product name, use, or date.
- A success rate with no denominator, endpoint, or follow-up.
- Advice to drop your meds or delay standard care.
- One protocol pitched for unrelated diseases.
- Rush to pay before you see the plan, consent form, or quote.
In its U.S. consumer alert, FDA warns about misleading claims for unapproved regenerative products and the risk that patients may be misled about safety and effectiveness. The warning does not determine the legal status of a particular Japanese clinic. Consumer alert regenerative medicine products including stem cells and exosomes
The bottom line
CPC registration is not proof of treatment effectiveness. Use the facility record to check the processing site, the plan or product documents to check regulatory status, and matching human studies to assess benefit and harm. If a clinic supplies only its registration number, the efficacy question remains unanswered.
Not sure what a facility paper actually covers in your case?
Ask which facility and treatment-plan documents are available for the service you are considering. Take those documents and any efficacy claims to your treating physician before making a decision.
This article is general information, not medical advice. It does not endorse any clinic, product, or protocol. Cell treatments carry risks and none is guaranteed to work. Speak with a licensed physician who knows your history, and do not stop or delay standard care on your own.
Sources
- Ministry of Health, Labour and Welfare (Japan). Specific Cell-Processed Product Manufacturing Facilities (Overview). Accessed October 27, 2026. https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_iryou/iryou/saisei_iryou/manufacturiungfacility.html
- Ministry of Health, Labour and Welfare (Japan). Enforcement Status of the Act on the Safety of Regenerative Medicine, as of June 30, 2026. Accessed October 24, 2026. https://www.mhlw.go.jp/content/001590173.pdf
- Pharmaceuticals and Medical Devices Agency (Japan). Regenerative Medical Products: Regulatory Framework. Accessed October 27, 2026. https://www.pmda.go.jp/english/review-services/reviews/0003.html
- Ministry of Health, Labour and Welfare (Japan). Regenerative and Cell Medicine and Gene Therapy. Accessed October 24, 2026. https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_iryou/iryou/saisei_iryou/index.html
- Ministry of Health, Labour and Welfare (Japan). Information on Regenerative Medicine Providers. Accessed October 24, 2026. https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000186471.html
- Pharmaceuticals and Medical Devices Agency (Japan). Review Reports: Regenerative Medical Products. Accessed October 24, 2026. https://www.pmda.go.jp/english/review-services/reviews/approved-information/0004.html
- Pharmaceuticals and Medical Devices Agency (Japan). Stemirac for Injection: Review Report. 2018. Accessed October 27, 2026. https://www.pmda.go.jp/files/000231946.pdf
- Whittle SL, Johnston RV, McDonald S, Worthley D, Campbell TM, Cyril S, Bapna T, Zhang J, Buchbinder R. Stem cell injections for osteoarthritis of the knee. Cochrane Database of Systematic Reviews. 2025;4(4):CD013342. PubMed record accessed October 27, 2026. https://pubmed.ncbi.nlm.nih.gov/40169165/
- Pharmaceuticals and Medical Devices Agency (Japan). List of Approved Regenerative Medical Products: April 2015 to May 2026. Accessed October 24, 2026. https://www.pmda.go.jp/files/000281990.pdf
- U.S. Food and Drug Administration. Important Patient and Consumer Information About Regenerative Medicine Therapies. Content current as of April 8, 2024. Accessed October 27, 2026. https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/important-patient-and-consumer-information-about-regenerative-medicine-therapies
- U.S. National Library of Medicine. Journal Selection for MEDLINE. Last reviewed July 24, 2026. Accessed October 27, 2026. https://www.nlm.nih.gov/medline/medline_journal_selection.html
- U.S. Food and Drug Administration. Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. Dated July 22, 2020. Accessed October 27, 2026. https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/consumer-alert-regenerative-medicine-products-including-stem-cells-and-exosomes




